SPDR S&P Biotech ETF (XBI) Holdings
XBI holdings summary
as of Oct 25, 2026- Holdings
- 157 positions listed
- Top 10 weight
- 17.6% of net assets
- Effective holdings
- 90 equal-weight equivalent
- Largest holding
- MRNA 2.19% Moderna, Inc.
- Annual turnover
- 63.8% of the portfolio traded
Top 1017.6%
Top 2539.1%
Top 5067.7%
Top 10092.3%
All XBI holdings
157 holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | MRNA | Moderna, Inc. | Healthcare | 2.19% | $226.4M | $87.04B | — |
| 2 | HALO | Halozyme Therapeutics, Inc. | Healthcare | 1.78% | $183.9M | $13.83B | 35.6 |
| 3 | UTHR | United Therapeutics Corporation | Healthcare | 1.76% | $182.7M | $22.87B | 19.1 |
| 4 | BIIB | Biogen Inc. | Healthcare | 1.75% | $181.3M | $34.37B | 41.3 |
| 5 | NTRA | Natera, Inc. | Healthcare | 1.74% | $180.1M | $56.71B | — |
| 6 | EXEL | Exelixis, Inc. | Healthcare | 1.73% | $179.2M | $15.42B | 19.6 |
| 7 | AMGN | Amgen Inc. | Healthcare | 1.73% | $178.9M | $233.82B | 26.9 |
| 8 | ABBV | AbbVie Inc. | Healthcare | 1.70% | $176.5M | $504.37B | 80.6 |
| 9 | IOVA | Iovance Biotherapeutics, Inc. | Healthcare | 1.61% | $167.0M | $6.17B | — |
| 10 | SYRE | Spyre Therapeutics, Inc. | Healthcare | 1.61% | $167.0M | $7.47B | — |
| 11 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 1.59% | $165.1M | $126.66B | 28.9 |
| 12 | GILD | Gilead Sciences, Inc. | Healthcare | 1.58% | $164.1M | $193.67B | — |
| 13 | TWST | Twist Bioscience Corporation | Healthcare | 1.58% | $164.1M | $8.80B | — |
| 14 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 1.49% | $154.6M | $81.41B | 19.6 |
| 15 | PTGX | Protagonist Therapeutics, Inc. | Healthcare | 1.47% | $152.7M | $8.33B | 125.0 |
| 16 | PTCT | PTC Therapeutics, Inc. | Healthcare | 1.46% | $151.4M | $4.94B | — |
| 17 | CRSP | CRISPR Therapeutics AG | Healthcare | 1.40% | $145.4M | $4.76B | — |
| 18 | ALKS | Alkermes plc | Healthcare | 1.40% | $145.4M | $6.92B | 108.5 |
| 19 | TGTX | TG Therapeutics, Inc. | Healthcare | 1.40% | $145.3M | $8.26B | 19.6 |
| 20 | ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | 1.38% | $142.7M | $31.02B | 39.1 |
| 21 | KRYS | Krystal Biotech, Inc. | Healthcare | 1.37% | $141.8M | $9.37B | 39.7 |
| 22 | ORKA | Oruka Therapeutics, Inc. | Healthcare | 1.36% | $140.4M | $4.76B | — |
| 23 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 1.34% | $138.7M | $13.79B | 19.9 |
| 24 | ROIV | Roivant Sciences Ltd. | Healthcare | 1.33% | $137.8M | $24.22B | — |
| 25 | BBIO | BridgeBio Pharma, Inc. | Healthcare | 1.33% | $137.7M | $12.98B | — |
| 26 | INCY | Incyte Corporation | Healthcare | 1.32% | $136.9M | $22.92B | 14.4 |
| 27 | RVMD | Revolution Medicines, Inc. | Healthcare | 1.30% | $134.8M | $38.14B | — |
| 28 | MDGL | Madrigal Pharmaceuticals, Inc. | Healthcare | 1.28% | $132.4M | $10.39B | — |
| 29 | BMRN | BioMarin Pharmaceutical Inc. | Healthcare | 1.26% | $130.6M | $10.58B | 147.8 |
| 30 | PCVX | Vaxcyte, Inc. | Healthcare | 1.25% | $129.9M | $10.01B | — |
| 31 | GRAL | GRAIL, Inc. | Healthcare | 1.25% | $129.3M | $5.26B | — |
| 32 | CYTK | Cytokinetics, Incorporated | Healthcare | 1.25% | $129.1M | $8.61B | — |
| 33 | ERAS | Erasca, Inc. | Healthcare | 1.23% | $127.8M | $4.68B | — |
| 34 | COGT | Cogent Biosciences, Inc. | Healthcare | 1.21% | $125.3M | $5.12B | — |
| 35 | KYMR | Kymera Therapeutics, Inc. | Healthcare | 1.19% | $123.1M | $8.62B | — |
| 36 | BCTG | BCTG Acquisition Corp | Financial Services | 1.19% | $123.0M | — | — |
| 37 | KOD | Kodiak Sciences Inc. | Healthcare | 1.15% | $118.9M | $5.39B | — |
| 38 | TVTX | Travere Therapeutics, Inc. | Healthcare | 1.15% | $118.8M | $4.61B | — |
| 39 | IONS | Ionis Pharmaceuticals, Inc. | Healthcare | 1.14% | $118.4M | $7.14B | — |
| 40 | DNTH | Dianthus Therapeutics, Inc. | Healthcare | 1.14% | $117.8M | $4.03B | — |
| 41 | PRAX | Praxis Precision Medicines, Inc. | Healthcare | 1.11% | $114.6M | $6.75B | — |
| 42 | RYTM | Rhythm Pharmaceuticals, Inc. | Healthcare | 1.10% | $114.0M | $5.91B | — |
| 43 | MIRM | Mirum Pharmaceuticals, Inc. | Healthcare | 1.07% | $111.0M | $5.20B | — |
| 44 | VCYT | Veracyte, Inc. | Healthcare | 1.06% | $109.4M | $3.47B | 30.8 |
| 45 | ARWR | Arrowhead Pharmaceuticals, Inc. | Healthcare | 1.05% | $108.9M | $7.90B | — |
| 46 | INSM | Insmed Incorporated | Healthcare | 1.05% | $108.7M | $21.02B | — |
| 47 | ARQT | Arcutis Biotherapeutics, Inc. | Healthcare | 1.03% | $106.8M | $3.62B | 131.0 |
| 48 | NK | NantKwest Inc | Healthcare | 1.03% | $106.8M | — | — |
| 49 | CGON | CG Oncology, Inc. | Healthcare | 0.93% | $96.3M | $5.31B | — |
| 50 | CDNA | CareDx, Inc | Healthcare | 0.88% | $91.4M | $3.31B | 30.8 |
| 51 | VKTX | Viking Therapeutics, Inc. | Healthcare | 0.87% | $90.5M | $3.20B | — |
| 52 | RLAY | Relay Therapeutics, Inc. | Healthcare | 0.86% | $89.5M | $3.57B | — |
| 53 | BEAM | Beam Therapeutics Inc. | Healthcare | 0.86% | $88.9M | $2.42B | — |
| 54 | RARE | Ultragenyx Pharmaceutical Inc. | Healthcare | 0.85% | $88.0M | $1.43B | — |
| 55 | SRRK | Scholar Rock Holding Corporation | Healthcare | 0.80% | $82.4M | $4.86B | — |
| 56 | CELC | Celcuity Inc. | Healthcare | 0.76% | $79.0M | $2.77B | — |
| 57 | DYN | Dyne Therapeutics, Inc. | Healthcare | 0.67% | $69.0M | $2.66B | — |
| 58 | AGIO | Agios Pharmaceuticals, Inc. | Healthcare | 0.64% | $66.7M | $1.87B | — |
| 59 | IMVT | Immunovant, Inc. | Healthcare | 0.63% | $65.3M | $5.52B | — |
| 60 | SLS | SELLAS Life Sciences Group, Inc. | Healthcare | 0.62% | $64.4M | $2.02B | — |
| 61 | RXRX | Recursion Pharmaceuticals, Inc. | Healthcare | 0.58% | $60.1M | $1.86B | — |
| 62 | IDYA | IDEAYA Biosciences, Inc. | Healthcare | 0.58% | $60.1M | $3.17B | — |
| 63 | NRIX | Nurix Therapeutics, Inc. | Healthcare | 0.57% | $59.3M | $2.67B | 10.0 |
| 64 | IRON | Disc Medicine, Inc. | Healthcare | 0.57% | $59.1M | $2.18B | — |
| 65 | SMMT | Summit Therapeutics Inc. | Healthcare | 0.57% | $58.6M | $11.67B | — |
| 66 | DNLI | Denali Therapeutics Inc. | Healthcare | 0.56% | $58.4M | $2.81B | — |
| 67 | VERA | Vera Therapeutics, Inc. | Healthcare | 0.56% | $58.3M | $2.01B | — |
| 68 | VRDN | Viridian Therapeutics, Inc. | Healthcare | 0.56% | $58.3M | $2.16B | — |
| 69 | BCRX | BioCryst Pharmaceuticals, Inc. | Healthcare | 0.54% | $56.0M | $1.99B | — |
| 70 | BHVN | Biohaven Ltd. | Healthcare | 0.53% | $55.1M | $1.63B | — |
| 71 | SRPT | Sarepta Therapeutics, Inc. | Healthcare | 0.53% | $54.9M | $1.81B | — |
| 72 | PURR | Hyperliquid Strategies Inc | Financial Services | 0.52% | $54.1M | $2.52B | 2.8 |
| 73 | ADMA | ADMA Biologics, Inc. | Healthcare | 0.51% | $53.3M | $2.39B | 15.3 |
| 74 | ACAD | ACADIA Pharmaceuticals Inc. | Healthcare | 0.49% | $51.2M | $3.29B | 8.6 |
| 75 | QURE | uniQure N.V. | Healthcare | 0.49% | $50.6M | $1.51B | — |
| 76 | VCEL | Vericel Corporation | Healthcare | 0.48% | $49.8M | $2.05B | 85.4 |
| 77 | NTLA | Intellia Therapeutics, Inc. | Healthcare | 0.47% | $48.4M | $1.60B | — |
| 78 | CLDX | Celldex Therapeutics, Inc. | Healthcare | 0.46% | $47.8M | $2.16B | — |
| 79 | NVAX | Novavax, Inc. | Healthcare | 0.45% | $46.7M | $1.86B | — |
| 80 | ABSI | Absci Corporation | Healthcare | 0.45% | $46.7M | $1.42B | — |
| 81 | PVLA | Palvella Therapeutics, Inc | Healthcare | 0.45% | $46.2M | $1.73B | — |
| 82 | NKTR | Nektar Therapeutics | Healthcare | 0.40% | $41.3M | $1.22B | — |
| 83 | RCUS | Arcus Biosciences, Inc. | Healthcare | 0.40% | $41.2M | $2.82B | — |
| 84 | TRAX | First Tracks Biotherapeutics | Healthcare | 0.38% | $38.9M | $1.23B | — |
| 85 | PGEN | Precigen, Inc. | Healthcare | 0.37% | $38.8M | $2.28B | — |
| 86 | XNCR | Xencor, Inc. | Healthcare | 0.35% | $36.2M | $1.70B | — |
| 87 | IMNM | Immunome, Inc. | Healthcare | 0.35% | $36.0M | $1.94B | — |
| 88 | STOK | Stoke Therapeutics, Inc. | Healthcare | 0.34% | $34.8M | $1.56B | — |
| 89 | SNDX | Syndax Pharmaceuticals, Inc. | Healthcare | 0.33% | $34.4M | $1.15B | — |
| 90 | ORIC | ORIC Pharmaceuticals, Inc. | Healthcare | 0.33% | $34.1M | $1.28B | — |
| 91 | ANAB | AnaptysBio, Inc. | Healthcare | 0.32% | $33.6M | $1.39B | — |
| 92 | INBX | Inhibrx, Inc. | Healthcare | 0.31% | $32.4M | $1.32B | — |
| 93 | MLYS | Mineralys Therapeutics, Inc. | Healthcare | 0.31% | $32.4M | $1.79B | — |
| 94 | ZBIO | Zenas BioPharma, Inc. | Healthcare | 0.31% | $31.7M | $1.62B | — |
| 95 | REPL | Replimune Group, Inc. | Healthcare | 0.29% | $30.5M | $1.02B | — |
| 96 | VIR | Vir Biotechnology, Inc. | Healthcare | 0.27% | $28.2M | $1.69B | — |
| 97 | JBIO | Jade Biosciences, Inc. | Healthcare | 0.26% | $26.8M | $856.7M | — |
| 98 | KURA | Kura Oncology, Inc. | Healthcare | 0.25% | $26.2M | $807.8M | — |
| 99 | TYRA_old | TYRA | Healthcare | 0.25% | $25.8M | — | — |
| 100 | ARDX | Ardelyx, Inc. | Healthcare | 0.24% | $25.2M | $797.8M | — |
| 101 | RIGL | Rigel Pharmaceuticals, Inc. | Healthcare | 0.23% | $24.3M | $858.7M | 2.7 |
| 102 | VSTM | Verastem, Inc. | Healthcare | 0.23% | $24.2M | $783.4M | — |
| 103 | MNKD | MannKind Corporation | Healthcare | 0.23% | $23.5M | $977.5M | — |
| 104 | GLUE | Monte Rosa Therapeutics, Inc. | Healthcare | 0.23% | $23.4M | $831.0M | — |
| 105 | ANNX | Annexon, Inc. | Healthcare | 0.22% | $23.0M | $646.5M | — |
| 106 | TSHA | Taysha Gene Therapies, Inc. | Healthcare | 0.21% | $22.2M | $1.18B | — |
| 107 | VOR | Vor Biopharma Inc. | Healthcare | 0.21% | $22.0M | $977.0M | 0.1 |
| 108 | GERN | Geron Corporation | Healthcare | 0.20% | $20.4M | $751.7M | — |
| 109 | JANX | Janux Therapeutics, Inc. | Healthcare | 0.20% | $20.2M | $1.01B | — |
| 110 | CADL | Candel Therapeutics, Inc. | Healthcare | 0.19% | $19.9M | $626.7M | — |
| 111 | CRVS | Corvus Pharmaceuticals, Inc. | Healthcare | 0.19% | $19.7M | $800.8M | — |
| 112 | BCAX | Bicara Therapeutics Inc. | Healthcare | 0.19% | $19.6M | $1.11B | — |
| 113 | COAG | Hemab Therapeutics Holdings, Inc. | Healthcare | 0.19% | $19.4M | $1.40B | — |
| 114 | CGEM | Cullinan Oncology, Inc. | Healthcare | 0.19% | $19.3M | $794.7M | — |
| 115 | IMMX | Immix Biopharma, Inc. | Healthcare | 0.17% | $17.8M | $661.6M | — |
| 116 | AVBP | ArriVent BioPharma, Inc. | Healthcare | 0.17% | $17.7M | $821.5M | — |
| 117 | KLRA | Kailera Therapeutics, Inc. | Healthcare | 0.17% | $17.7M | $1.46B | — |
| 118 | MYGN | Myriad Genetics, Inc. | Healthcare | 0.17% | $17.7M | $380.7M | — |
| 119 | DMRA | Damora Therapeutics, Inc. | Healthcare | 0.16% | $16.4M | $1.14B | — |
| 120 | OLMA | Olema Pharmaceuticals, Inc. | Healthcare | 0.15% | $15.5M | $575.7M | — |
| 121 | SVRA | Savara Inc. | Healthcare | 0.15% | $15.2M | $914.3M | — |
| 122 | FDMT | 4D Molecular Therapeutics, Inc. | Healthcare | 0.14% | $14.8M | $670.7M | — |
| 123 | ACHV | Achieve Life Sciences, Inc. | Healthcare | 0.14% | $14.5M | $657.8M | — |
| 124 | RGNX | REGENXBIO Inc. | Healthcare | 0.14% | $14.2M | $457.1M | — |
| 125 | PRME | Prime Medicine, Inc. | Healthcare | 0.13% | $13.5M | $629.4M | — |
| 126 | SANA | Sana Biotechnology, Inc. | Healthcare | 0.13% | $13.4M | $679.5M | — |
| 127 | CTMX | CytomX Therapeutics, Inc. | Healthcare | 0.12% | $12.9M | $496.8M | — |
| 128 | SGMT | Sagimet Biosciences Inc. | Healthcare | 0.12% | $12.9M | $568.7M | — |
| 129 | ALLO | Allogene Therapeutics, Inc. | Healthcare | 0.12% | $12.3M | $452.6M | — |
| 130 | IRWD | Ironwood Pharmaceuticals, Inc. | Healthcare | 0.12% | $12.0M | $578.3M | 4.5 |
| 131 | ELYM | Eliem Therapeutics Inc | Healthcare | 0.12% | $12.0M | — | — |
| 132 | TKM | Arbutus Biopharma Corp | Other | 0.11% | $11.9M | — | — |
| 133 | AVTX | Avalo Therapeutics, Inc. | Healthcare | 0.11% | $11.8M | $604.4M | — |
| 134 | CAPR | Capricor Therapeutics, Inc. | Healthcare | 0.11% | $11.5M | $390.1M | — |
| 135 | EDIT | Editas Medicine, Inc. | Healthcare | 0.11% | $11.4M | $360.9M | — |
| 136 | SLDB | Solid Biosciences Inc. | Healthcare | 0.11% | $11.4M | $593.0M | — |
| 137 | EBS | Emergent BioSolutions Inc. | Healthcare | 0.11% | $11.0M | $327.1M | — |
| 138 | MNPR | Monopar Therapeutics Inc. | Healthcare | 0.11% | $10.9M | $465.0M | — |
| 139 | STTK | Shattuck Labs, Inc. | Healthcare | 0.10% | $10.6M | $544.0M | — |
| 140 | SPRY | ARS Pharmaceuticals, Inc. | Healthcare | 0.10% | $10.0M | $399.8M | — |
| 141 | ALT | Altimmune, Inc. | Healthcare | 0.10% | $9.9M | $427.9M | — |
| 142 | DSGN | Design Therapeutics, Inc. | Healthcare | 0.09% | $9.7M | $645.2M | — |
| 143 | OCGN | Ocugen, Inc. | Healthcare | 0.09% | $9.2M | $264.6M | — |
| 144 | AKTS | Akoustis Technologies, Inc. | Healthcare | 0.09% | $9.2M | $837.6M | — |
| 145 | CABA | Cabaletta Bio, Inc. | Healthcare | 0.08% | $8.0M | $239.1M | — |
| 146 | PRTA | Prothena Corporation plc | Healthcare | 0.08% | $8.0M | $428.7M | — |
| 147 | VNDA | Vanda Pharmaceuticals Inc. | Healthcare | 0.07% | $7.4M | $243.7M | — |
| 148 | MDXG | MiMedx Group, Inc. | Healthcare | 0.07% | $7.3M | $646.5M | 110.8 |
| 149 | OVID | Ovid Therapeutics Inc. | Healthcare | 0.07% | $7.1M | $419.9M | — |
| 150 | NGNE | Neurogene Inc. | Healthcare | 0.07% | $7.0M | $465.3M | — |
| 151 | ASMB | Assembly Biosciences, Inc. | Healthcare | 0.06% | $6.7M | $409.0M | 19.3 |
| 152 | AURA | Aura Biosciences, Inc. | Healthcare | 0.06% | $6.6M | $632.6M | — |
| 153 | LXEO | Lexeo Therapeutics, Inc. | Healthcare | 0.05% | $4.7M | $216.7M | — |
| 154 | CBIO | Crescent Biopharma, Inc. | Healthcare | 0.04% | $4.5M | $439.8M | — |
| 155 | FTH | Faeth Therapeutics, Inc. | Healthcare | 0.04% | $4.5M | $485.8M | — |
| 156 | CMPX | Compass Therapeutics, Inc. | Healthcare | 0.04% | $4.0M | $154.9M | — |
| 157 | BBOT | BridgeBio Oncology Therapeutics, Inc. | Healthcare | 0.02% | $1.9M | $226.1M | — |
Weights as a percentage of net assets. Value held = weight × net assets ($10.36B). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
XBI sector breakdown
| Sector | Weight | Holdings | Largest |
|---|---|---|---|
| Healthcare | 97.9% | 154 | MRNA, HALO, UTHR |
| Financial Services | 1.7% | 2 | BCTG, PURR |
| Other | 0.1% | 1 | TKM |
Sum of the weights of the holdings in each sector.
XBI top industries
Biotechnology
80.7%
Drug Manufacturers - General
6.8%
Drug Manufacturers - Specialty & Generic
5.3%
Diagnostics & Research
5.1%
Shell Companies
1.2%
Capital Markets
0.5%
XBI overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IWM | iShares Russell 2000 ETF | 8.8% | 125 of 1,962 | 0.19% |
| QQQ | Invesco QQQ ETF | 3.3% | 6 of 101 | 0.17% |
| VTI | Vanguard Total Stock Market ETF | 2.4% | 151 of 2,941 | 0.03% |
| SPY | SPDR S&P 500 ETF | 1.9% | 8 of 502 | 0.09% |
| DIA | SPDR Dow Jones Industrial Average ETF | 1.7% | 1 of 30 | 0.16% |
| VXUS | Vanguard Total International Stock ETF | 0.1% | 3 of 8,035 | 0.05% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the XBI portfolio
SPDR S&P Biotech ETF holds 157 positions. The ten largest make up 17.6% of the fund and the top 50 67.7%, so it behaves like a portfolio of about 90 equally weighted stocks. The biggest positions are Moderna, Inc. (2.19%), Halozyme Therapeutics, Inc. (1.78%), United Therapeutics Corporation (1.76%), Biogen Inc. (1.75%), Natera, Inc. (1.74%).
By sector, Healthcare is 97.9%, Financial Services is 1.7%, Other is 0.1%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: XBI chart, XBI performance, XBI dividends, XBI overview.
XBI holdings FAQ
How many holdings does XBI have?
XBI holds 157 positions as of October 25, 2026.
What are the top 10 holdings of XBI?
The ten largest holdings are Moderna, Inc. (2.19%), Halozyme Therapeutics, Inc. (1.78%), United Therapeutics Corporation (1.76%), Biogen Inc. (1.75%), Natera, Inc. (1.74%), Exelixis, Inc. (1.73%), Amgen Inc. (1.73%), AbbVie Inc. (1.70%), Iovance Biotherapeutics, Inc. (1.61%), Spyre Therapeutics, Inc. (1.61%). Together they are 17.6% of the fund.
What percentage of XBI is Moderna, Inc.?
Moderna, Inc. is the largest holding at 2.19% of net assets, about $226.4M of the fund's $10.36B.
Which sector is the largest in XBI?
Healthcare is the largest sector at 97.9%, followed by Financial Services (1.7%) and Other (0.1%), based on the sectors of the individual holdings.
How concentrated is XBI?
The top 10 holdings are 17.6% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) XBI behaves like a portfolio of about 90 equally weighted stocks.